Abstract: Objective The aim of this study was to investigate the clinical significance of CDKN1C positive expression in bone marrow in patients with myelodysplastic syndrome and secondary acute myeloid leukemia.Methods 125 patients with MDS/AML were selected as the research subjects,and selected 20 healthy subjects as a healthy control group.The mRNA and protein expression levels of CDKN1C in CD34⁺ cells of MDS/AML patients were analyzed.The expression levels of CDKN1C were compared with those of MDS patients.The survival rate of patients with MDS and AML was analyzed by Cox regression analysis.The survival rate of MDS patients with different expression levels of CDKN1C was also analyzed.Results The expression of CDKN1C at levels of mRNA and protein in bone marrow CD34⁺ cells of MDS/AML patients were significantly higher than those in healthy controls(P＜0.05).There has a positive correction with BM(P＜0.05).The survival rate of CDKN1C high expression group was significantly lower than that in the low and mediate CDKN1C expression groups(P＜0.05).The results of Cox regression analysis showed that age,high BM count,cytogenetic difference and the positive expression of CDKN1C significantly affected the survival rate of patients with MDS/AML(P＜ 0.05);The survival rate of MDS/AML chemotherapy in the CDKN1C positive group was significantly lower than that of CDKN1C negative expression group(P＜0.05).The survival rate of MDS/AML after chemotherapy AlloSCT CDKN1C positive expression group was significantly lower than that of CDKN1C negative expression group(P＜0.05).Conclusion The expression of CDKN1C in bone marrow of MDS/AML patients was significantly increased,and the positive expression of CDKN1C significantly increased,and the positive expression of CDKN1C significantly affected the survival rate of MDS/AML patients.

Key words: CDKN1C, Myelodysplastic syndrome, Secondary acute myeloid leukemia, Bone marrow